# Cognitive Neurology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN-TD
- Date: 1984-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Mireille Haddad-Kowalski, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Langston Pryce-Okonjo, MD

## Reason for consultation

Two years of progressive memory loss with getting lost while driving in a retired professional boxer of 63 with type 2 diabetes and hypertension; MoCA 18. Please stage the impairment, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, advise on biomarker testing and on eligibility for anti-amyloid therapy, and help us plan safety and support. **S**

## History

Sugar Ray Robinson, a retired professional boxer of 63, is seen at the memory clinic with his care partner at the request of Dr. Pryce-Okonjo. He says his memory is not what it was but that this is normal at his age; his care partner describes two years of slowly worsening forgetfulness for recent events, repeated questions and stories, missed bills, and two episodes of getting lost while driving in familiar streets. There has been no sudden change, no hallucinations, no acting out of dreams, no falls and no change in personality, temper or mood. He boxed for about 25 years; he remembers many hard fights but cannot say how often he was dazed. He exercises daily and still goes to the gym of the youth foundation he started. **S**

## Examination

| System | Finding |
|---|---|
| Neurological | Cranial nerves normal; no rigidity, tremor, bradykinesia or dysarthria; normal strength, reflexes and coordination; steady narrow-based gait |
| Mental status | Alert and courteous; repeats questions; impaired delayed recall that cueing helps little; mild executive slowing; language and visuospatial copying preserved; no psychotic symptoms |

BP 128/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76.8 kg; BMI 23.7 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Pryce-Okonjo's intake note. MoCA 18 at intake (education point included); PHQ-9 4; Functional Activities Questionnaire 11. Blood count, metabolic panel, B12, TSH and urine albumin-to-creatinine ratio normal; hemoglobin A1c 6.4%. Brain MRI this morning: moderate bilateral hippocampal atrophy, left more than right, mild generalized atrophy, Fazekas 1 white matter change, six microbleeds at the gray-white junction of both frontal lobes and the right temporal lobe, no cortical superficial siderosis or infarct, and a cavum septi pellucidi. Audiometry this morning: mild to moderate bilateral high-frequency sensorineural hearing loss. No anticoagulant or antiplatelet drug. Today: MMSE 22; global CDR 1, sum of boxes 5.5. MMSE: 22; CDR (global): 1. All results are synthetic.

## Assessment

1. **Stage and pattern** (R41.3). Mild dementia (global CDR 1, MMSE 22, MoCA 18) with an amnestic presentation and progressive course, independent in personal care but dependent for complex tasks. With bilateral hippocampal atrophy, this is most consistent with Alzheimer's disease beginning before 65. Depression, thyroid disease, B12 deficiency and anticholinergic drugs have been excluded or addressed; sleep apnea risk is low; hearing loss is a treatable contributor. **S**
2. **Traumatic encephalopathy syndrome and vascular disease** (R41.3). Twenty-five years of professional boxing is substantial exposure to repetitive head impacts. Under the 1979 NINDS consensus criteria, traumatic encephalopathy syndrome is a research diagnosis for people with that exposure and progressive cognitive or neurobehavioral impairment; it is not meant to guide routine clinical care, and the underlying disease, chronic traumatic encephalopathy, can be confirmed only after death. He has no neurobehavioral dysregulation or parkinsonism, and the amnestic pattern with hippocampal atrophy points to Alzheimer's disease; repetitive head impacts may still add to his difficulty, as the microbleeds and cavum septi pellucidi suggest past injury. Vascular change is slight and does not explain his dementia. **S**
3. **Biomarkers and APOE**. Confirming Alzheimer's pathology will settle the diagnosis, which he wants, inform counseling and planning, and distinguish it from a mainly traumatic process. Amyloid PET is the test I advise. APOE genotyping informs the risk of amyloid-related imaging abnormalities for anti-amyloid therapy; since he is not a candidate, it would not change his care, and it carries implications for relatives. It can be offered with genetic counseling if he wishes. **S**
4. **Anti-amyloid therapy**. By stage and MMSE (20 to 30 for donanemab, 22 to 30 for lecanemab) he would otherwise fit, and he takes no anticoagulant. But both the lecanemab and donanemab appropriate use recommendations exclude people with more than four cerebral microbleeds on the pre-treatment MRI because of the risk of bleeding and amyloid-related imaging abnormalities. With six microbleeds he does not qualify, whatever his amyloid status. **S**
5. **Diabetes and blood pressure** (E11.9). Hemoglobin A1c 6.4% on glipizide is tighter than needed: for an older adult with cognitive impairment the ADA Standards advise a goal under 8.0% and avoiding drugs that cause hypoglycemia, which harms memory and raises the risk of falls. Blood pressure is well controlled. **S**
6. **Treatment, safety and support**. If amyloid is confirmed, a cholinesterase inhibitor offers modest benefit: donepezil 5 mg, then 10 mg after four to six weeks if tolerated, after a baseline ECG, watching for nausea, loose stools, vivid dreams and a slow pulse. Memantine is for moderate dementia. With CDR 1 and getting lost while driving, his driving risk is high and he should not drive. A firearm should not be kept in the home of a person with dementia. Hearing aids, exercise, social activity and support for his care partner, including respite, matter as much as medicine. **S**

## Recommendations

1. Amyloid PET to confirm Alzheimer's disease pathology; disclosure of the result with his care partner present if he wishes.
2. Not a candidate for lecanemab or donanemab: more than four microbleeds on MRI; APOE genotyping not needed for treatment and offered only with genetic counseling.
3. Traumatic encephalopathy syndrome recorded as a consideration only; it is a research diagnosis and does not change treatment.
4. If amyloid is positive: donepezil 5 mg after a baseline ECG, raised to 10 mg after four to six weeks if tolerated; step back to 5 mg, or take it in the morning, for nausea, diarrhea, vivid dreams or a slow pulse.
5. Stop glipizide and keep metformin, with a hemoglobin A1c goal under 8.0%.
6. No driving; remove the firearm from the home.
7. Hearing aids for both ears.
8. Care partner education and respite, with the Alzheimer's Association 24/7 Helpline and an adult day program; the GUIDE dementia care model once he has Medicare.
9. Advance care planning soon, while he can take part fully.
10. MoCA and CDR yearly, or sooner with change; repeat MRI only for an acute change.

## Strengths and supports

- Strengths and supports: discipline and daily exercise, pride in his career, a warm and sociable manner, his care partner, friends from boxing, and the young people at the foundation **S**

## Communication

Discussed with Dr. Pryce-Okonjo, who saw him the same day. The findings were explained to him and his care partner; he agreed to the amyloid PET, declined APOE testing, and agreed not to drive until the results visit. **S**

## Follow-up

Dr. Pryce-Okonjo will review the PET result with him at the six-week visit and continue his care; the memory clinic will see him again in a year, or sooner if he declines faster than expected or behavioral symptoms appear. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- Lecanemab: Appropriate Use Recommendations (2023), J Prev Alzheimers Dis 2023;10(3):362-377 (Cummings J et al.)
- Donanemab: Appropriate use recommendations (2025), J Prev Alzheimers Dis 2025;12(5):100150 (Rabinovici GD et al.)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863
- 13. Older Adults: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S277-S296)
- Practice Parameter update: Evaluation and management of driving risk in dementia (2010), American Academy of Neurology (Neurology 2010;74(16):1316-1324)
- Guiding an Improved Dementia Experience (GUIDE) Model (2024), Centers for Medicare & Medicaid Services, Innovation Center
